Who are Celldex Therapeutics, Inc.'s main suppliers?

Celldex Therapeutics, Inc. (CLDX) key suppliers include: CDMOS, LEERINK-PARTNERS-LLC, TD-SECURITIES-USA-LLC, iBio, Inc., Pyxis Oncology, Inc. and 1 more. View the full supplier network at chainsifter.com/chain/CLDX.

Who are Celldex Therapeutics, Inc.'s major customers?

Celldex Therapeutics, Inc. (CLDX) key customers include: ROCKEFELLER-UNIVERSITY, Pyxis Oncology, Inc., Arcus Biosciences, Inc., Sanofi, Sanofi and 1 more. View the full customer network at chainsifter.com/chain/CLDX.

What sector is Celldex Therapeutics, Inc. in?

Celldex Therapeutics, Inc. (CLDX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CLDX Supply Chain: Celldex Therapeutics, Inc. Supplier List & 13 Relationships

6Suppliers

6Customers

1Debt Items

20Related Chains

Celldex Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CDMOS	CDMOS	92%	We rely on CDMOs over whom we have limited control. Should the cost, delivery and quality of clinical materials manufactured by us in our Fall River facility or supplied by CDMOs vary to our disadvan…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	92%	On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
TD-SECURITIES-USA-LLC	TD-SECURITIES-USA-LLC	92%	On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for ma…
PYXS	Pyxis Oncology, Inc.	72%	Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS g…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS g…

Celldex Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
ROCKEFELLER-UNIVERSITY	ROCKEFELLER-UNIVERSITY	90%	The Company recognized $ 0.0 million and $ 0.6 million in revenue under the agreements with Rockefeller during the three months ended March 31, 2026, and 2025, respectively.
PYXS	Pyxis Oncology, Inc.	72%	Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
SNYNF	Sanofi	72%	gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drugs or import bans. The regulatory requirements and policies may change and additiona…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYN…
KOLLTAN-PHARMACEUTICALS-INC	KOLLTAN-PHARMACEUTICALS-INC	62%	ce obligations in the contract; and ● Recognition of revenue when, or as, the Company satisfies a performance obligation. Revenue for the Company is derived from product development agreements with c…

Celldex Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CLDX-DEBT	Debt stack $1.9M	90%	Market cache reports total debt of $1.9M.

Celldex Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CLDX-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP	WELLINGTON MANAGEMENT GROUP LLP	90%	13F overlay lists WELLINGTON MANAGEMENT GROUP LLP as top holder; 232 tracked holders.

Celldex Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ATOS	Atossa Therapeutics, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
BBIO	BridgeBio Pharma, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2

Celldex Therapeutics, Inc. Supply Chain